Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.61 |
| ▸ | ABL1 | P00519 | 13/20 | 0.57 |
| ▸ | BCR | P11274 | 13/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5752653 | 0.86 | MEN1 (0.56) | MEN1KMT2ATRPV1ABL1BCR | |
| SCHEMBL3910196 | 0.86 | MEN1 (0.60) | MEN1KMT2ATRPV1ABL1BCR | |
| SCHEMBL5923911 | 0.85 | TRPV1 (0.56) | MEN1KMT2ATRPV1ABL1BCR | |
| SCHEMBL4109259 | 0.84 | MEN1 (0.66) | MEN1KMT2AABL1BCRNPC1 | |
| SCHEMBL5752589 | 0.84 | TRPV1 (0.63) | MEN1KMT2ATRPV1ABL1BCR | |
| SCHEMBL5923900 | 0.84 | TRPV1 (0.65) | MEN1KMT2ATRPV1ABL1BCR | |
| SCHEMBL1013229 | 0.84 | TRPV1 (0.65) | MEN1KMT2ATRPV1ABL1BCR | |
| SCHEMBL28001138 | 0.80 | ABL1 (0.67) | MEN1KMT2AABL1BCR | |
| SCHEMBL25479846 | 0.79 | MEN1 (0.58) | MEN1KMT2AABL1BCRNPC1 | |
| SCHEMBL5473957 | 0.79 | MEN1 (0.62) | MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651619-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMIN ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005009977-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMINA ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-02-03 | — | — | WO | claimed |
| US-20060229308-A1 | Substituted pyrirmidin-4-ylamine analogues as vanilloid receptor ligands | NEUROGEN CORPORATION (US) | 2006-10-12 | — | — | US | disclosed |
| EP-1651619-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMIN ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009977-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMINA ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229308-A1 | Substituted pyrirmidin-4-ylamine analogues as vanilloid receptor ligands | TRPV1, GPR17, TRPV2 | MEN1 4029/4885KMT2A 3244/4885TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.